PPG introduces PPG LINQ Color software and PPG MAGICBOX body shop assistant for the refinish industry
30.8.2023 16:00:00 EEST | Business Wire | Press release
PPG (NYSE: PPG) today announced the introduction of PPG LINQ™ Color software and the PPG MAGICBOX™ body shop assistant for smarter wireless mixing in automotive repair shops. The advanced tools are the latest components of the PPG LINQ end-to-end digital solution for the global refinish industry that provide productivity and sustainability improvement for body shops.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830721690/en/
The PPG MAGICBOX™ smart device eliminates the need for specialized computers in the mixing room by delivering a PPG patented body shop assistant, connectable to new and existing USB scales in body shops. (Photo: Business Wire)
With PPG LINQ, refinish customers can streamline their repair process by using PPG’s cloud-based platform and its interconnected digital hardware, software and related services. The PPG MagicBox body shop assistant is a small but powerful device that communicates environmental conditions in mixing rooms and receives formulas direct from the PPG LINQ Color software. These new tools also extend the digital ecosystem to smaller body shops not previously served by the PPG LINQ solution.
The PPG LINQ system delivers benefits including faster color-matching from any internet-connected device; less rework and no need for spray-out cards; faster and more efficient paint mixing; and waste reduction, when compared to a traditional repair process.
“When our PPG LINQ digital ecosystem is paired with our industry-leading paint products, we can help body shop owners to realize a 15% ‘key-to-key’ productivity improvement,” said Chancey Hagerty, PPG senior vice president, Automotive Refinish. “From the time a customer leaves their key with a body shop until they return to collect their car, that body shop can achieve improved productivity, reduced waste and enhanced sustainability compared to a traditional repair approach.”
The launch of PPG LINQ Color software and the PPG MagicBox body shop assistant follows the launch of other PPG LINQ digital ecosystem products, including PPG VISUALIZID™ software, the PPG DIGIMATCH™ spectrophotometer and the PPG MOONWALK® system, the company’s award-winning, automated paint mixing system launched in 2019.
“Today, thousands of body shops around the globe already use the PPG MoonWalk, PPG VisualizID and PPG DigiMatch tools,” said Alban d’Epenoux, PPG global marketing director, Automotive Refinish. “The addition of PPG LINQ Color software and the PPG MagicBox device can also mean additional productivity and enhanced capabilities for those existing users and also for thousands of other body shops interested in adopting the best digital solutions to enhance their business performance.”
To learn more about the PPG LINQ digital solution, visit https://ppglinq.com.
PPG: WE PROTECT AND BEAUTIFY THE WORLD®
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and materials that our customers have trusted for 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $17.7 billion in 2022. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.
PPG LINQ, MagicBox, Digimatch, and VisualizID are trademarks, and MoonWalk, the PPG Logo and We Protect and Beautify the World are registered trademarks of PPG Industries Ohio, Inc.
CATEGORY Automotive Refinish
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230830721690/en/
Contact information
Michelle Deemer
Automotive Refinish
+1 412 728 0195
mdeemer@ppg.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
